TITLE:
Clinical Research Progress of Crohn
AUTHORS:
Pingping Mei, Wenzhe Feng, Peng Shi, Yu Zhuang, Wenxiu Zhang
KEYWORDS:
Crohn, Crohn’s Drug Treatment, Mesenchymal Stem Cells
JOURNAL NAME:
Journal of Biosciences and Medicines,
Vol.10 No.8,
August
5,
2022
ABSTRACT: Crohn’s Disease (CD) is a chronic recurrent inflammatory bowel disease with unknown etiology, most common in the terminal ileum and adjacent colon. In the past 30 years, the global prevalence of CD has continued to rise. Although the etiology is unknown, studies have shown that it is closely related to geographical environment, microfold cell damage, intestinal flora changes, epithelial barrier damage, immune dysfunction and low. The main clinical manifestations of CD are abdominal pain, chronic diarrhea, fatigue, fever and weight loss. At present, 5-aminosalicylic acid, antibiotics, glucocorticoids, immunosuppressants and biological agents are mainly used for treatment, but the drug effect is limited and the effect is not good. Recent studies have shown that Mesenchymal Stem Cells (MSC) can down-regulate immune response and promote tissue healing, which has certain safety and effectiveness in the treatment of moderate and severe CD, and has broad application prospects, but also has certain limitations. This paper summarizes the application and efficacy of related therapies in CD, providing a reference for clinicians.